Redefining resectability in pancreatic cancer after neoadjuvant therapy: are we any closer?
Editorial Commentary

Redefining resectability in pancreatic cancer after neoadjuvant therapy: are we any closer?

Francis P. Robertson1,2^, Sanjay Pandanaboyana1,3

1Department of HPB and Transplant Surgery, Newcastle Upon Tyne NHS Foundation Trust, Freeman Hospital, Newcastle Upon Tyne, UK; 2Division of Surgery and Interventional Science, University College London, Royal Free Campus, London, UK; 3Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK

^ORCID: 0000-0001-5016-5944.

Correspondence to: Sanjay Pandanaboyana. HPB and Transplant Unit, Freeman Hospital, Newcastle Upon Tyne NE7 7DN, UK. Email:

Comment on: Oba A, Del Chiaro M, Satoi S, et al. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci 2022;29:725-31.

Keywords: Pancreatic cancer; resectability; neoadjuvant therapy (NAT)

Submitted Dec 30, 2022. Accepted for publication Jan 09, 2023. Published online Jan 16 2023.

doi: 10.21037/hbsn-22-638

Pancreatic resection with negative margins offers the only potential cure within a multimodal treatment strategy that includes chemotherapy with or without radiotherapy for patients with pancreatic cancer. Traditionally the definition of resectability in pancreatic cancer was focused on the location of the tumour to major vascular structures surrounding the head of pancreas as described by a variety of organisations around the world, with subtle differences in definitions for resectable, borderline resectable and locally advanced pancreatic cancers (1). Our understanding of pancreatic cancer has evolved from ‘surgical resection with negative margins offering the only potential hope of a cure’ to managing pancreatic cancer as a systemic disease from the outset. The adoption of neoadjuvant therapy (NAT) has become standard practice in many pancreatic centres worldwide and recent evidence has shown improved overall survival and disease free survival in patients with all stages of pancreatic cancer (2). The adoption of NAT provides clinicians with a window of opportunity to observe and identify patients with favourable tumour biology as demonstrated by control of tumour growth by chemotherapy. The definition of resectability in pancreatic cancer therefore requires to be updated for patients undergoing NAT to include an assessment of tumour biology. This issue was addressed by Dr. Oba and colleagues at the symposium ‘New criteria of resectability for pancreatic cancer’ which was held during the 33rd meeting of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) (3). The aim of this symposium was to bring together experts in the field of locally advanced pancreatic cancer with western and eastern experience to reach a consensus opinion of which factors should be included to address updated guidelines on resectabilty in pancreatic cancer that reflects recent developments in defining resectability after NAT. This is particularly important as we continue to accumulate evidence supporting NAT for borderline resectable pancreatic cancer (4,5).

This symposium has considered patient fitness for surgery as based on the Eastern Cooperative Oncology Group (ECOG) which has been shown to be an independent predictor of survival in patients with pancreatic cancer (6). This highlights a role for prehabilitation programmes in patients with borderline resectable and locally advanced pancreatic cancer. Although early results from studies have shown that such programmes might improve post-operative outcomes it effect on overall survival remains to be seen (7). This symposium has focused however on a dynamic assessment of tumour biology to be taken into consideration along with an anatomical assessment of resectability.

Identifying tumour response by imaging remains challenging. The ability to identify tumour regression based on the RECIST criteria remains difficult as viable tumour is replaced by fibrotic or inflammatory tissue (8). There is evidence that the use of positron emitted tomography/computed tomography (PET-CT) can help identify tumour response with a drop in maximum Standardised Uptake Values (SUVmax) following NAT demonstrating a response to chemotherapy (9). These results have been confirmed by further large studies (10) demonstrating that reduced metabolic activity in pancreatic cancer following NAT as demonstrated on CT PET is an accurate measure of tumour response and is associated with improved survival.

The use of MRI in pancreatic imaging is increasing and MRI PET like CT PET can accurately identify reduced metabolic activity highlighting disease response in locally advanced pancreatic cancer (11). A pilot study from The Netherlands has shown, that 3 Tesla (3 T) contrast enhanced and diffusion weighted (DWI) magnetic resonance imaging (MRI) was more sensitive than CT at identifying tumour response following NAT (12). They described a Halo sign where viable tumour was replaced by fibrotic tissue. A higher R0 resection rate was seen in patients with a HALO sign but this was not statistically significant (66.7% vs. 20.0%, P=0.242). Although promising, the study was limited to 20 patients and larger studies are required to confirm these findings. The identification of patients with fibrosis at the resection margin rather than viable tumour would facilitate the selection of those likely to undergo a R0 resection which is associated with improved survival (5).

The role of endoscopic ultrasound scan (EUS) and elastography was not explored in this symposium but EUS has been shown to play an important role in the diagnosis of pancreatic cancer and to provide an accurate assessment of the stage of tumour (13). EUS has shown promise at assessing tumour response/progression in patients with gastric cancer following NAT (14). Despite some promising results (15) at assessing tumour response following NAT in pancreatic cancer its role remains to be fully elucidated. A European multicentre study (PEACE) is currently underway exploring the utility of contrast enhanced ultrasound (CEUS) as a predictor of treatment efficiency in locally advance pancreatic cancer and results may further confirm the utility of CEUS in this setting.

Whilst decreasing CA19-9 levels have been shown to reflect response to chemotherapy in some studies (16) results are conflicting (17) and not all patients have elevated CA19-9 levels prior to commencing chemotherapy. This symposium has highlighted a lack of serum markers to identify tumour response. There is ongoing work investigating molecular subtypes of pancreatic cancer through EUS guided biopsy of the tumour. Molecular subtyping of pancreatic cancer has identified that different subtypes with varying response profiles to treatment and overall survival (18) however this is yet to be translated to serum biomarkers that can assess response to NAT. Similarly Micro RNAs have been investigated in the setting of patients with inoperable pancreatic cancer undergoing palliative chemotherapy (19) and has shown promise at mapping response to treatment. The role of micro RNAs however in assessing response in patients with LA pancreatic cancer remains to be elucidated. The conclusions of this symposium were rightly that further work is required to develop biomarkers to assess tumour response to NAT to help identify those patients with favourable tumour biology.

Pancreatic resection for PDAC is shifting towards a more aggressive surgical approach for fewer patients. Whilst the evidence supports that major vascular resection can be safely carried out and is associated with improved overall survival (20) it is also associated with higher morbidity rates. Patient selection is therefore paramount to focus such aggressive surgical approaches on patients with favourable tumour biology and those likely to undergo a R0 resection that may benefit instead an aggressive surgical approach following NAT. This symposium represents a transition in our understanding that patient selection for pancreatic resection no longer relies on anatomical considerations but a functional assessment of tumour biology. With results from the ESPAC5 trial reporting a survival benefit following NAT in borderline resectable pancreatic cancer (4), it is likely that this will become the standard of care and it is paramount that restaging after treatment is standardised. A multi-modal approach will be required and further research studies are essential to identify a combination of blood biomarkers and imaging modalities such as MRI, PET-CT and CEUS that predict tumour response to NAT to facilitate improved patient selection and therefore improve patient outcomes.


Funding: None.


Provenance and Peer Review: This article was commissioned by the editorial office, Hepatobiliary Surgery and Nutrition. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See:


  1. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018;18:2-11. [Crossref] [PubMed]
  2. da Costa WL Jr, Tran Cao HS, Gu X, et al. Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma. Ann Surg 2022;275:415-21. [Crossref] [PubMed]
  3. Oba A, Del Chiaro M, Satoi S, et al. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci 2022;29:725-31. [Crossref] [PubMed]
  4. Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:157-68. [Crossref] [PubMed]
  5. van Veldhuisen E, Klompmaker S, Janssen QP, et al. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Ann Surg Oncol 2022; Epub ahead of print. [Crossref] [PubMed]
  6. Tas F, Sen F, Odabas H, et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2013;18:839-46. [Crossref] [PubMed]
  7. Bundred JR, Kamarajah SK, Hammond JS, et al. Prehabilitation prior to surgery for pancreatic cancer: A systematic review. Pancreatology 2020;20:1243-50. [Crossref] [PubMed]
  8. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015;261:12-7. [Crossref] [PubMed]
  9. Barnes CA, Aldakkak M, Clarke CN, et al. Value of Pretreatment (18)F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Front Oncol 2020;10:500. [Crossref] [PubMed]
  10. Abdelrahman AM, Goenka AH, Alva-Ruiz R, et al. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. J Natl Compr Canc Netw 2022;20:1023-1032.e3. [Crossref] [PubMed]
  11. Panda A, Garg I, Truty MJ, et al. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival. AJR Am J Roentgenol 2021;217:730-40. [Crossref] [PubMed]
  12. Stoop TF, van Veldhuisen E, van Rijssen LB, et al. Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): prospective pilot study. Langenbecks Arch Surg 2022;407:3487-99. [Crossref] [PubMed]
  13. Gonzalo-Marin J, Vila JJ, Perez-Miranda M. Role of endoscopic ultrasound in the diagnosis of pancreatic cancer. World J Gastrointest Oncol 2014;6:360-8. [Crossref] [PubMed]
  14. Hoibian S, Giovannini M, Autret A, et al. Preoperative EUS evaluation of the response to neoadjuvant therapy for gastric and esophagogastric junction cancer is correlated with survival: A single retrospective study of 97 patients. Endosc Ultrasound 2021;10:103-10. [Crossref] [PubMed]
  15. Barreto SG, Loveday B, Windsor JA, et al. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ J Surg 2019;89:481-7. [Crossref] [PubMed]
  16. Chiorean EG, Von Hoff DD, Reni M, et al. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol 2016;27:654-60. [Crossref] [PubMed]
  17. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008;9:132-8. [Crossref] [PubMed]
  18. Collisson EA, Bailey P, Chang DK, et al. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 2019;16:207-20. [Crossref] [PubMed]
  19. Meijer LL, Frampton AE, Garajová I, et al. Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma. Lancet 2017;389:S68. [Crossref]
  20. Ravikumar R, Sabin C, Abu Hilal M, et al. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg 2014;218:401-11. [Crossref] [PubMed]
Cite this article as: Robertson FP, Pandanaboyana S. Redefining resectability in pancreatic cancer after neoadjuvant therapy: are we any closer? Hepatobiliary Surg Nutr 2023;12(1):131-134. doi: 10.21037/hbsn-22-638

Download Citation